• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

VIDEO: Platelet Transfusions Increase Risk of Death and Arterial Thrombosis among Patients with TTP and HIT

January 30, 2015

Today we will be discussing risks associated with platelet transfusions for patients with rare, immune-mediated platelet consumptive disorders.

Thrombotic thrombocytopenic purpura, or TTP, is a life-threatening condition characterized by the formation of clots in small blood vessels throughout the body. Heparin-induced thrombocytopenia, or HIT, is a rare and severe reaction to heparin that leads to platelet activation and thrombin formation. Immune thrombocytopenic purpura, or ITP, causes less serious bleeding and bruising, and usually resolves without treatment.

Using the Nationwide Inpatient Sample database, a new study reviewed nearly 100,000 hospital records of patients with TTP, HIT and ITP.

Here is Dr. Takemoto, who is one of the study authors:

“Because these conditions are so rare, hematologists have little to go on when deciding how to treat them. Some data suggests that transfusions may be harmful for these patients.”

Data on platelet transfusions for patients with TTP, HIT and ITP is currently lacking. Nevertheless, researchers found that 10% of TTP patients, 7% of HIT patients and 26% of ITP patients received platelet transfusions.

Platelet transfusions, however, were associated with adverse events for many of these patients.

Dr. King, who is another study author, explains:

“Platelet transfusions increased the odds of dying in the hospital five-fold for patients with HIT and doubled the odds for patients with TTP, even after adjusting for age and gender. Arterial thrombosis was also higher in patients with TTP and HIT who received a platelet transfusion. We found no associations for ITP patients and platelet transfusions.”

Platelet transfusions are commonly administered to sicker patients who are bleeding. However, the results remained significant after adjusting for clinical severity.
Until further studies are available, Dr. Takemoto advises:

“Platelet transfusions should be used only for emergencies: invasive procedures, surgeries or severe bleeding in TTP and HIT patients. For HIT patients, the first step is to stop administering heparin and.for TTP patients,plasma exchange therapy should be initiated.”

We’ll be back with another edition of Transfusion News on February 15. Thanks for joining us.

Reference

1. Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AAR. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality: nationally representative data from 2007-2011. Blood 2015; in press.

Filed Under

  • Adverse Events (non-infectious)
  • Featured
  • Platelet Transfusion
  • Special Transfusion Situations
  • Videos

Recommended

  • Convalescent Plasma Donors Needed for COVID-19

  • Platelet Counts Decrease during Pregnancy but Severe Thrombocytopenia is Rare

  • Clinical Guidelines for Platelet Transfusions in Patients with Cancer

Show Comments

Reader Interactions

Comments

  1. Dr. Ken Groshart says

    February 9, 2015 at 7:45 pm

    Agree. Would include aHUS, APAS (tho unusual to get platelet counts below 40-50K unless catastrophic transition) and HELLP syndrome (personal experience with one case only)

  2. Reuben Wafula Welanunu says

    March 17, 2015 at 8:24 am

    True, platelet transfusion and / or any component transfusions should only be administered after carefully weighing the transfusion benefits Versus the potential harm to the recipient.

  3. lisa says

    March 25, 2015 at 8:42 pm

    yes. I have TTP, I WAS DIAGNOSED IN JULY 2013. I WAS DOING FINE UNTIL 1YR. AND A , HALF LATER I COULD NOT FORM A SENTENCE SO I HAD MY BLOOD CHECKED MY PLATELETS WERE AT 9,000 I WAS IN DEEP TROUBLE I WAS BACK IN THE HOSP. 4 DAYS,OUT OF HOSP THEN THE VERY NEXT WEEK WAS BACK IN THE HOSPITAL, FOR 2 WEEKS THREW XMAS And went home on new years eve….I got a long journey ahead and will accept all ,and any advise that is helpful to my situation rightnow I am on chemo drug called vinacristine I have already been on rituxin that only teased my blood my no. were up and now my ADAMST13 IS LESS THAN 3

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley